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Introduction
Menopause is a status characterized with decrease in 
estrogen and increase in ferritin levels. As serum estrogen 
is known to prevent the prevalence of atherosclerosis, 
postmenopausal women are at high risk of developing 
cardiovascular disease (CVD). Consequently, CVD including 
coronary artery disease (CAD) and strokes contribute to have 
higher morbidity and mortality rates in postmenopausal 
women.1 
Prevalence of high levels of thyroid stimulating hormone 
(TSH) increases with age, especially after menopause.2 
Thyroid hormonal level abnormally increases in this group 
because of decrease in serum estrogen levels. Moreover, 
symptoms occurring due to thyroid disease are similar 
to postmenopausal symptoms, that differentiating these 
two diseases is difficult. On top of that, missing thyroid 
dysfunction in postmenopausal women would more increase 
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Objectives: Menopause is a natural aging process causing estrogen deficiency, accelerating atherogenic processes including 
dyslipidemia. Prevalence of thyroid dysfunction is also high in postmenopausal women, and it is known to elevate the risk of 
cardiovascular disease (CVD). Therefore, we are to study on the associations in between serum thyroid stimulating hormone (TSH) 
and prevalence of CVD in postmenopausal women who have normal thyroid function.
Methods: We performed a retrospective review of 247 Korean postmenopausal women who visited the health promotion center 
from January, 2007 to December, 2009. Postmenopausal women with normal serum TSH were included in the study. Coronary 
atherosclerosis was assessed by 64-row multidetector computed tomography. 
Results: In multiple linear regression analysis, serum TSH was associated with serum triglyceride (TG) (β = 0.146, P = 0.023). 
In multiple logistic regression analysis, increasing age and serum TSH were associated with an increased risk of coronary 
atherosclerosis in euthyroid postmenopausal women (odds ratio [OR] = 1.107 [1.024-1.197], P = 0.011 and OR = 1.303 [1.024-1.658], 
P = 0.031, respectively).
Conclusions: It revealed that significant predictor of serum TSH was serum TG, and increasing age and TSH were found to have 
associations with an increased risk of coronary atherosclerosis in euthyroid postmenopausal women. Screening and assessing risks 
for CVD in healthy postmenopausal women would be helpful before atherosclerosis develops. (J Menopausal Med 2016;22:146-153)
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the risk of CVD. Therefore, routine screening of thyroid 
function in postmenopausal women would be crucial.
Thyroid hormone has both direct and indirect actions 
on heart and vascular systems. Both hypothyroidism and 
hyperthyroidism have been studied to cause detrimental 
effects in cardiovascular system. Also, from previous studies, 
invasive and noninvasive measurements of thyroid function 
in women having thyroid disease are known to be closely 
linked to cardiac functions such as heart rate, cardiac output 
and systemic vascular resistance.2 Serum TSH has also been 
to have positive associations with serum total cholesterol (TC), 
low-density lipoprotein cholesterol (LDL-C), non-high-
density lipoprotein cholesterol (non-HDL-C), triglycerides 
(TG) and negative association with serum HDL-C.3 
Based on these facts, a question raises whether 
associations exist in between serum TSH and prevalence of 
CVD in postmenopausal women who have normal thyroid 
function. However, not many studies on this field have 
been investigated. Therefore, this study was undertaken 
to determine whether serum TSH levels are associated 
with coronary atherosclerosis in euthyroid postmenopausal 
women. 
Materials and Methods
1. Participants
This is a retrospective study of postmenopausal women, 
who attended health care center at Severance Hospital, 
Seoul, Korea for routine check-up from January, 2007 to 
December, 2009. We included postmenopausal women over 
40 years old, who are at menopause, defined as 12 months 
of amenorrhea. Before recruitment, their postmenopausal 
status were once more confirmed with serum follicle 
stimulating hormone (FSH) levels ≥ 40 IU/L, and all 
of them required to have normal thyroid function with 
normal serum free T4 (fT4). Exclusion criteria included 
participants who are currently smoking, and those who 
were diagnosed with hypertension (HTN), diabetes mellitus 
(DM), hypercholesterolemia, and CVD. Women who were 
receiving menopausal hormone therapy (MHT) were also 
excluded. A total of 247 participants who satisfied above 
criteria were included in the study. The study was carried 
out in accordance with the ethical standards of the Helsinki 
Declaration, and was approved by the Yonsei University 
Health System, Severance Hospital, Institutional Review 
Board.
Height and body weight were measured with light 
clothing, and body mass index (BMI) was calculated as 
weight (kg) divided by square meters of height (m2). Blood 
pressure (BP) was measured using an automated device 
(TM-2665P; A&D Co., Ltd., Tokyo, Japan) in a sitting 
position, after 10 minutes of rest. All participants had 
serum blood test after 8 hours of fasting, including glucose, 
TC, TG, HDL-C, LDL-C, glucose, white blood cell (WBC), 
C-reactive protein (CRP), uric acid, gamma-glutamyl 
transferase (γGT), alkaline phosphatase (ALP), bilirubin, 
estradiol (E2), FSH, TSH, and fT4.
2. Coronary artery assessment
Cardiac computed tomography (CT) was performed 
using a 64-multidetector-row CT (MDCT) scanner 
(Philips Brilliance 64; Philips Medical System, Best, the 
Netherlands). In women with a heart rate of ≥ 70 beats/
minute, a β-blocker (40-80 mg of propranolol hydrochloride; 
Pranol, Dae Woong, Seoul, Korea) was administered orally 
1 hour before the scan. Images were reconstructed on the 
scanner’s work station using commercially available software 
(Extended Brilliance Workstation, Philips Medical System). 
Coronary atherosclerosis was defined if there is any size 
of calcified, or non-calcified, atherosclerotic plaque with 
luminal narrowing. 
3. Statistical analysis
Baseline characteristic of the participants were expressed 
as the mean ± standard deviation (SD). In order to find 
clinical variables that are related to serum TSH, bivariate 
correlation analysis was done for Pearson’s correlation 
coefficients. Based on the findings, multiple regression 
analysis was performed. To find independent parameters to 
the presence of coronary atherosclerosis, stepwise multiple 
logistic regression analysis was conducted. 
All statistical analyses were conducted using SPSS ver. 
15.0 (SPSS Inc., Chicago, IL, USA). A P value less than 0.05 
was considered to be statistically significant. 
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Results
Baseline characteristics of the subjects are displayed on 
Table 1. The mean age was 55.40 ± 5.80 years old and the 
mean serum TSH was 2.16 ± 1.59 mcIU/mL. The mean 
serum FSH and E2 were 80.84 ± 25.07 mIU/mL and 10.17 
± 9.98 pg/mL, respectively. The mean BMI was 22.90 ± 
2.36 kg/m2, and mean lipid profiles were as follows; TC 
204.21 ± 31.93 mg/dL, HDL-C 57.89 ± 13.21 mg/dL, 
LDL-C 129.40 ± 30.31 mg/dL, and TG 98.09 ± 58.94 mg/
dL. Among 247 postmenopausal women, 22 people (8.90%) 
were found to have coronary atherosclerosis. 
We were to investigate on association in between serum 
TSH level and clinical variables using simple correlation 
analysis. Age, TG were weakly positively correlated (r = 
0.148, P = 0.020 and r = 0.169, P = 0.008, respectively), 
and HDL-C was weakly negatively correlated (r = -0.145, P 
= 0.023) with serum TSH (Table 2). Based on these findings, 
multiple linear regression analysis was done, and it revealed 
that serum TSH was associated with serum TG (β = 0.146, 
P = 0.023). Although they were not significant, serum TSH 
also had tendency to have associations with age and serum 
HDL-C (Table 3). 
To find factors which independently affect on presence of 
coronary atherosclerosis, stepwise multiple logistic regression Table 1. Baseline characteristics of 247 euthyroid postmenopausal 
women
Variables Mean ± SD
TSH (mcIU/mL) 2.16 ± 1.59
Age (years) 55.40 ± 5.80
BMI (kg/m2) 22.90 ± 2.36
SBP (mmHg) 117.32 ± 16.54
DBP (mmHg) 72.57 ± 9.93
FSH (mIU/mL) 80.84 ± 25.07
E2 (pg/mL) 10.17 ± 9.98
Glucose (mg/dL) 90.39 ± 9.85
Calcium (mg/dL) 8.86 ± 0.45
Coronary atherosclerosis, n (%) 22 (8.9)
WBC (103/μL) 5.05 ± 1.34
CRP (mg/L) 1.31 ± 2.30
Uric acid (mg/dL) 4.40 ± 0.87
ALP (IU/L) 65.25 ± 19.69
Total bilirubin (mg/dL) 0.87 ± 0.29
γ-GT (IU/L) 26.98 ± 59.68
Total cholesterol (mg/dL) 204.21 ± 31.93
HDL-cholesterol (mg/dL) 57.89 ± 13.21
LDL-cholesterol (mg/dL) 129.40 ± 30.31
Triglyceride (mg/dL) 98.09 ± 58.94
SD: standard deviation, TSH: thyroid stimulating hormone, BMI: 
body mass index, SBP: systolic blood pressure, DBP: diastolic 
blood pressure, FSH: follicle-stimulating hormone, E2: estradiol, 
WBC: white blood cell, CRP: C-reactive protein, ALP: alkaline phos-
phatase, γ-GT: gamma-glutamyl transferase, HDL: high-density 
lipoprotein, LDL: low-density lipoprotein
Table 2. Pearson’s correlation coefficients between serum thyroid 
stimulating hormone and clinical variables
Variables r P value
Age (years) 0.148 0.020
BMI (kg/m2) 0.034 0.596
SBP (mmHg) 0.033 0.602
DBP (mmHg) 0.016 0.806
FSH (mIU/mL) 0.040 0.533
E2 (pg/mL) -0.041 0.521
Glucose (mg/dL) 0.061 0.340
Calcium (mg/dL) -0.079 0.218
WBC (103/μL) 0.015 0.811
CRP (mg/L) -0.043 0.496
Uric acid (mg/dL) -0.003 0.958
ALP (IU/L) 0.060 0.346
Total bilirubin (mg/dL) 0.043 0.500
γ-GT (IU/L) 0.053 0.411
Total cholesterol (mg/dL) -0.028 0.660
HDL-cholesterol (mg/dL) -0.145 0.023
LDL-cholesterol (mg/dL) -0.033 0.650
Triglyceride (mg/dL) 0.169 0.008
BMI: body mass index, SBP: systolic blood pressure, DBP: diastolic 
blood pressure, FSH: follicle-stimulating hormone, E2: estradiol, 
WBC: white blood cell, CRP: C-reactive protein, ALP: alkaline phos-
phatase, γ-GT: gamma-glutamyl transferase, HDL: high-density 
lipoprotein, LDL: low-density lipoprotein
Journal of Menopausal Medicine 2016;22:146-153
149
Seung Joo Chon, et al. TSH, Atherosclerosis in Postmenopausal Woman
https://doi.org/10.6118/jmm.2016.22.3.146
analysis was conducted. Firstly, in simple logistic regression 
analysis, age, systolic BP (SBP), serum TSH, total bilirubin, 
and HDL-C were statistically significantly associated with 
presence of coronary atherosclerosis in postmenopausal 
women (Table 4). Based on these data, multiple logistic 
regression analysis was done. It revealed that increasing age 
and serum TSH were associated with an increased risk of 
coronary atherosclerosis in postmenopausal woman (odds 
ratio [OR] = 1.107 [1.024-1.197], P = 0.011 and OR = 1.303 
[1.024-1.658], P = 0.031, respectively). On the other hand, 
SBP, serum total bilirubin, and HDL-C did not have any 
association with prevalence of coronary atherosclerosis (Table 
5). 
Discussion
The findings of the present study indicate that serum 
TSH levels could be considered as an independent predictive 
marker of the presence of coronary atherosclerosis in 
euthyroid postmenopausal women. Also, serum TSH levels 
within a normal range may be associated with age and some 
lipid profiles in these women. These findings suggest that 
increase in age, TG and decrease in HDL-C levels may be 
related to TSH elevation, and these changes would lead to 
higher risk of having coronary atherosclerosis in healthy 
postmenopausal women. 
Menopause is a natural aging process causing estrogen 
deficiency. In premenopausal period, women have a 
significantly lower risk for CVD compared to postmenopausal 
women or age matched men.4 However, after menopause, 
decline in serum estrogen accelerates atherogenic processes, 
including dyslipidemia, endothelial dysfunction, arterial 
stiffness, and increase the risk for CVD, which threaten 
women’s health.5 This disparity between prevalence of CVD 
Table 3. Multiple regression analysis for serum thyroid stimulating 
hormone
Variables β P value β P value
Age (years) 0.128 0.058 0.121 0.060
HDL-cholesterol (mg/dL) -0.118 0.068
Triglyceride (mg/dL) 0.146 0.023
HDL: high-density lipoprotein
Table 5. Multiple logistic regression analysis for the presence of 
coronary atherosclerosis in postmenopausal women
Variables OR P value
Age 1.107 (1.024-1.197) 0.011
SBP 1.020 (0.992-1.049) 0.171
TSH 1.303 (1.024-1.658) 0.031
Total bilirubin 3.536 (0.881-14.198) 0.075
HDL-cholesterol 0.981 (0.942-1.022) 0.360
OR: odds ratio, SBP: systolic blood pressure, TSH: thyroid stimu-
lating hormone, HDL: high-density lipoproteinTable 4. Simple logistic regression analysis for the presence of 
coronary atherosclerosis in euthyroid postmenopausal women
Variables OR P value
Age 1.139 (1.061-1.222) < 0.001
BMI 0.962 (0.794-1.166) 0.691
SBP 1.027 (1.002-1.051) 0.032
DBP 1.041 (0.998-1.086) 0.064
FSH 1.002 (0.984-1.019) 0.863
E2 1.012 (0.979-1.047) 0.473
Glucose 0.993 (0.949-1.040) 0.776
TSH 1.379 (1.134-1.721) 0.002
WBC 1.059 (0.765-1.467) 0.729
CRP 0.627 (0.326-1.207) 0.162
Uric acid 1.028 (0.614-1.721) 0.916
ALP 1.001 (0.979-1.024) 0.910
Total bilirubin 4.184 (1.133-15.451) 0.032
γ-GT 1.004 (0.990-1.010) 0.108
Total cholesterol 0.993 (0.979-1.007) 0.300
HDL-cholesterol 0.959 (0.923-0.995) 0.027
LDL-cholesterol 0.989 (0.974-1.004) 0.146
Triglyceride 1.004 (0.998-1.010) 0.179
OR: odds ratio, BMI: body mass index, SBP: systolic blood pres-
sure, DBP: diastolic blood pressure, FSH: follicle-stimulating 
hormone, E2: estradiol, TSH: thyroid stimulating hormone, WBC: 
white blood cell, CRP: C-reactive protein, ALP: alkaline phospha-
tase, γ-GT: gamma-glutamyl transferase, HDL: high-density lipo-
protein, LDL: low-density lipoprotein
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in premenopausal and postmenopausal women has been 
elucidated to the actions of estrogens on cardiovascular 
system, particularly on vascular endothelium. Previous 
studies have reported that both endogenous and exogenous 
estrogens have cardio-protective effects in premenopausal 
women and women starting estrogen therapy within the 
first few years after menopause, whereas initiating estrogen 
therapy many years after menopause may have hazardous 
effects on cardiovascular systems.6~8 Like this, actions 
of estrogen depends on the time of initiation of estrogen 
therapy in postmenopausal women, and it may be due to 
endothelial injury, changes in vascular estrogen receptor 
expression, intracellular signaling which could alter the 
cardiovascular effects of this steroid hormone.9 Although 
risk and benefit of HRT since the first announcement of 
Women's Health Initiative study in 2002 were controversial, 
hormone replacement therapy in young menopausal women 
could decrease the morbidity and mortality related to 
coronary heart disease and stroke.10 Also in one previous 
study, early menopausal women are known to face more 
physiological problems than the late menopausal women on 
their quality of life.11
In an aspect of lipid profiles, as women go through 
menopause, TC, LDL-C, TG, very LDC-C (VLDL-C) 
increase and HDL-C decreases contributing to form 
atherogenesis.1 In these women, small dense LDL particles 
also increase, which would further increase the coronary 
atherosclerosis in euthyroid postmenopausal women. In 
this study, in simple logistic regression analysis, increasing 
HDL-C seemed to have associations with a decrease in 
presence of coronary atherosclerosis (OR = 0.959 [0.923-
0.995], P = 0.027) in euthyroid postmenopausal women, 
although it was not valid in multiple logistic regression 
analysis (OR = 0.981 [0.942-1.022], P = 0.360). These 
negative effects on women’s lipid profiles increase and 
positive effects on women’s lipid profiles tend to decrease 
risks of CVD that screening for CVD is essential and should 
also include healthy postmenopausal women.
Prevalence of thyroid dysfunction appears to be high in 
postmenopausal woman.12 Thyroid dysfunction is diagnosed 
by measuring of the serum thyrotropin which is known 
as TSH, and it is known as the best and the most reliable 
test to diagnose thyroid disease.13,14 Thyroid dysfunction 
is defined based on clinical signs, symptoms, and serum 
TSH level.15 In the Study of Women’s Health Across the 
Nation (SWAN), serum TSH levels outside the normal range 
were found to be up to 9.4% in women aged from 42 to 
52 years old. Also, serum TSH statistically increased in 
3.5%, for each 5 years as age increases.16 Elevated serum 
TSH is common in postmenopausal women, and clinical 
symptoms caused by abnormal thyroid function could be 
masked by postmenopausal symptoms. It is known that 
estrogen influences on serum thyroid hormone by increasing 
the level of thyroxine binding globulin, with the decrease 
of its clearance.17 Therefore, routine screening of thyroid 
function in menopausal period to determine thyroid disease 
is required.
Thyroid dysfunction is associated with diverse aspects 
of metabolic abnormalities and conditions such as obesity, 
hypercholesterolemia, osteoporosis, and CVD.18~20 Many 
studies have investigated on mechanisms of thyroid hormone 
on cardiovascular system. Thyroid hormone is known to 
cause cardiac contractility both directly and indirectly, by 
increasing peripheral oxygen consumption and substrate 
requirements.21~23 Triiodothyronine, the active cellular 
form of thyroid hormone, is known to decrease systemic 
vascular resistance through vasodilation by direct effecting 
on vascular smooth muscle cells promoting relaxations.24,25 
Thyroid hormone also increases blood volume.26 As systemic 
vascular resistance decreases, the effective arterial filling 
volume falls, which causes increase in renin secretion and 
activation of the angiotensin-aldosterone axis. Then, it 
eventually stimulates renal sodium reabsorption and finally 
increases plasma volume.27
Patients with hyperthyroidism mainly have decrease in 
systemic vascular resistance, and increase in resting heart 
rate, left ventricular contractility, ejection fraction, and blood 
volume, which overall increase cardiac output, higher than 
in normal population.26,28 On the other hand, hemodynamic 
changes in hypothyroidism are opposite to the ones in 
hyperthyroidism. The usual signs are bradycardia, decrease 
in ventricular filling with decrease in cardiac contractility 
causing low cardiac output.29 Although hypothyroidism 
presents milder clinical symptoms than hyperthyroidism, 
it may cause accelerated atherosclerosis and CAD.30 In 
one population-based cross-sectional study, subclinical 
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hypothyroidism was found to be a strong risk factor for 
atherosclerosis and myocardial infarction in postmenopausal 
women.31
It is clear that abnormal thyroid function is a risk for 
CVD, but whether thyroid function within the reference 
range would also be associated with cardiovascular risk has 
to be evaluated. In one cross-sectional study with 2,205 
postmenopausal women, upper normal range of serum 
TSH (2.48-4.00 mIU/L) showed 1.95 of adjusted OR for 
prevalence of metabolic syndrome.3 Our study revealed that 
serum TSH was associated with serum TG (β = 0.146, P 
= 0.023). Like our study, one cross-sectional study with 
1333 people with euthyroidism, people with serum TSH in 
upper normal range (2.5-4.5 mIU/L) had higher TG, with 
1.7-fold increase in prevalence of metabolic syndrome.32 
There were also studies on associations in between serum 
TSH and BP in euthyroid people. One study concluded that 
people with higher levels of TSH within a normal range, 
had more elevated BP than people with lower normal serum 
TSH range, whereas other study on 1,319 euthyroid people 
concluded that there is no association in between serum 
TSH and BP.33~35 
Among many factors associated with cardiovascular risk 
factors, recent studies report on a direct effect of serum 
TSH in upper normal range to increase in arterial stiffness 
in euthyroid dialysis patients.36 Serum TSH is known to 
increase circulating inflammatory molecules and to inhibit 
nitric oxide production due to oxidative stress.37,38 Like 
previous study, our study found that increasing age and 
TSH level were associated with an increased risk of coronary 
atherosclerosis in euthyroid postmenopausal women, having 
OR = 1.107 (1.024-1.197), P = 0.011 and OR = 1.303 (1.024-
1.658), P = 0.031, respectively. Since serum TSH is easy to 
evaluate with blood sampling, measuring serum TSH would 
be an economical and convenient method of screening high 
risk group for CVD.
This study bears certain limitations. First, it is a 
retrospective study based on chart review, that causal 
associations cannot be demonstrated. Second, the studied 
subjects are from a single institution with restricted sample 
size. Korean people are known to have higher intake of 
iodine than people in other countries. Iodine is a substrate 
requiring for synthesis of thyroid hormones. It induces 
thyroid hormone secretion by inhibiting the proteolytic 
release of iodothyronines from thyroglobulin, and also 
reduces thyroid cellularity and vascularity affecting on 
serum thyroid hormones. Therefore, applying our study’s 
result to people with other ethnicity having different 
lifestyles may not be appropriate. Third, we only included 
people who visited health care center in a tertiary hospital 
which would not fully present general population of Korean 
people. Therefore, applying our results to everyone would 
not be possible, but to certain group of postmenopausal 
women would be meaningful.
In conclusion, it revealed that significant predictor of 
serum TSH was serum TG, and increasing age and TSH 
were found to have associations with an increased risk 
of coronary atherosclerosis in euthyroid postmenopausal 
women. As life span is extended in these days, for even 
in healthy postmenopausal women, screening and risk 
assessment for CVD and proper management of modifiable 
risk factors would be required before atherosclerosis 
develops.
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